Suzhou-headquartered biotechnology firm Tot Biopharm, which focuses on high-end anti-tumour drugs, has raised $102 million in a Series B funding round co-led by existing investor Chengwei Capital, asset manager 99Fund, and China Universal (Cayman) GP Ltd.
The latest funding round was also joined by investors that joined in earlier rounds, including Center Laboratories Group, Vivo Capital, Yuanta Financial Holdings Group, and Cathay Capital.
